Drug Trend Report 2020: Tackling hyperinflation | CVS Health

Tackling hyperinflation

Manufacturers often take unjustified price hikes on existing drugs simply by introducing different formulations or dosing recommendations. These are often known as “hyperinflated.” Regardless of what they are called, spending on these drugs means wasted dollars for our clients. 

We proactively manage this for our clients to help ensure drug cost savings. We do it automatically as part of our formulary management process on our client’s behalf.

Statistics: 72 drugs removed in 2020. $1.2 billion lower client spend compared to 2018. Since 2019, our hyperinflation strategy has saved $1.32 PMPM.